Galactokinase deficiency [one of three known forms of the disease galactosemia (1)] is inherited as an autosomal recessive trait with a heterozygote frequency estimated to be 0.2% in the general population (2). The major clinical manifestation ofgalactokinase deficiency is neonatal cataract formation (1), apparently due to galactitol accumulation (3). Presenile cataracts might also result from galactokinase deficiency (4) .
The gene responsible for galactokinase deficiency galactosemia has not been determined, and thus the precise molecular alterations responsible for this disease are uncharacterized. A human galactokinase gene, GKI, has been previously mapped to human chromosome 17 by assaying galactokinase activity in cell extracts from mouse-human hybrid cell lines (5) (6) (7) (8) . It is not known if GKI is altered in patients with galactokinase deficiency.
Galactokinase (EC 2.7.1.6) serves the same function in yeast as in bacteria and humans, phosphorylation of galactose in the pathway for use of this sugar as a carbon source (9) . We have therefore sought to clone a human galactokinase gene by its ability to substitute for the yeast enzyme. Several mammalian cDNAs have recently been identified by complementation or other functional activity in yeast (see refs. 10-12) . We report here the cloning of a cDNA that encodes human galactokinase § by complementation of a galactokinase-deficient (gall -) strain of Saccharomyces cerevisiae. We have made the unexpected finding that this gene, GK2, does not map to chromosome 17. It is thus not clear whether the locus responsible for galactokinase deficiency disease affects GKI or GK2.
MATERIALS AND METHODS
Yeast Strains, Media, and Transformation. The recipient yeast strain used in transformations was S. cerevisiae YM20 (MATa ura3-1 ura3-2 trpl-289 his3-532 ade2-l(ochre) galldell (8, (22) (23) (24) (25) (26) . Total human genomic DNA was a gift of Margit Burnmeister (University of Michigan, Ann Arbor, MI). DNA samples from human-mouse hybrid cell lines A59-3Aaz10a and MH22-6 were obtained from Huntington Willard (Stanford University, Palo Alto, CA) and Pragna Patel (Baylor University), respectively. The Hs27 (newborn human foreskin) cell line was obtained from the ATCC (CRL 1634). Primers for detecting the human 32-microglobulin gene (B2M) were B2MI (5'-CAC-CCAGTCTAGTGCATGCCTTCT-3') and B2M2 (5'-TGAGAAGGAAGTCACGGAGCGAGA-3') and for detecting the human gastrin gene (GAS) were GAS1 (5'-ATGCTAGTCG-GTGTAGAGCCATG-3') and GAS2 (5'-TTGTACCTCAT-AGGGCTGCGTGA-3') (27) .
RESULTS
Isolation of a Human cDNA Clone by Complementation in Yeast. A HepG2 cDNA expression library was introduced into yeast strain YM20, which contains a deletion of the gene encoding galactokinase (GAL)). Transformants were plated on medium containing galactose as carbon source to select for transformants with galactokinase activity. One transformant was identified in =150,000 transformants tested.
We first determined whether growth on galactose medium was plasmid dependent by selecting for cells that had lost this plasmid by growth on plates containing 5-fluoroorotic-acid (28) . Cells cured ofthe plasmid were no longer able to grow on galactose medium (data not shown). A plasmid, designated pJJGK, was isolated from the original yeast transformant by transformation into bacteria and then reintroduced into yeast strain YM20. All Ura+ transformants grew on galactose medium, suggesting that this plasmid encoded a galactokinase.
The cDNA insert ofpJJGK was sequenced, which revealed a single large open reading frame with the potential to encode a 458-amino acid polypeptide of 50,386 daltons ( Fig. 1 ). This polypeptide (denoted GK2) shows extensive similarity to galactokinase from yeasts and bacteria: 29%o overall identity (matches/458) to the GAL) protein of Saccharomyces carlsbergensis (29) , 31% to GAL) of Kluyveromyces lactis (30), 22% to galK of E. coli (31), 21% to galK of Lactobacillus helveticus (32) , and 16% to GK of Streptomyces lividans (33) (Fig. 2) . Alignment of these sequences revealed at least six regions (A-F) with particularly striking amino acid identity. For from total human genomic DNA (Fig. 4A) . The PCR products from pJJGK and from human genomic DNA were cleaved into identical fragments by Stu I (R.T.L., unpublished observations). Genomic DNA from a panel of well-characterized human-rodent somatic cell hybrids (Table 1) retaining   FIG. 3 . Phylogenetic tree for galactokinase and galactokinaserelated proteins of human, yeast, and bacteria. Symbols are as in Fig.  2 . The tree was constructed by the progressive alignment method (20) . The lengths of horizontal lines are a measure of divergence. subsets of human chromosomes was used as a template for PCR (8, (22) (23) (24) (25) (26) . The presence of an amplified PCR fragment was perfectly correlated with the presence of human chromosome 15 in the hybrid lines but not with chromosome 17, on which the GKJ gene resides (5) (6) (7) (8) . Of seven hybrids that lack chromosome 15 but contain chromosome 17, none yielded an amplified fragment. In contrast, the one line with chromosome 15 but not chromosome 17 (A59-3AazlOa; Fig.  4A, lane 23) yielded an amplified fragment. The only common chromosome in lines NA 09940 and A59-3AazlOa is chromosome 15. These observations argue that the GK2 gene resides on chromosome 15.
To verify the chromosome composition of our somatic cell hybrid panel, we carried out a similar PCR analysis using primers (27) for genes known to reside on either chromosome 15 or 17, .2-microglobulin (B2M) and gastrin (GAS) genes, respectively. PCR primers for B2M amplified a 357-bp fragment only from DNA of cell lines reported to contain chromosome 15 (Table 1 and Fig. 4B) . Amplification data for Fig. 2 ), as has been previously noted (31, 32) . The greatest sequence and length variability occurs between regions C and D, making it unlikely that this region contains the catalytic site or site for binding ATP. Region F contains a G-rich sequence (GXGXXG) preceding a lysine residue that has been suggested to be an ATP-binding site (31, 33, 34) . The GK2 open reading frame also shows similarities to the S. cerevisiae GAL3 gene (35) 17 (7) and earlier data (6) rule out the possibility that chromosome 17 carries a positive regulator of the gene on chromosome 15. It is simplest to imagine that there are at least two galactokinase genes, GKI on chromosome 17 and GK2 on chromosome 15. If chromosome 17 indeed contains a structural gene for agalactokinase, we might expect it to have similarity to GK2, based on the extensive conservation of sequence observed in bacteria, yeasts, and humans. Our assay for the presence of a sequence related to GK2 used only one set of primers for PCR and might not have detected a genomic segment that encodes a large intron. PCR analysis with different primers and low-stringency hybridization analyses should clarify these questions.
If humans have two different galactokinase genes, one might expect to observe galactokinase isozymes. Enzymological studies of human galactokinase do not give a clear answer to the number of isozymes (37, 38) . There is also uncertainty about the molecular mass [38 kDa (39) vs. 55 kDa (40) ] and subunit structure of galactokinase [monomer (39) vs. perhaps dimer (40) ]. The predicted molecular mass of a GK2 polypeptide chain is 50.4 kDa.
Our observations raise anew the question ofthe location of the genetic determinant for galactokinase deficiency disease: Does it reside on chromosome 15 or on chromosome 17? Chromosome transfer experiments using chromosomes from humans with galactokinase-deficiency galactosemia have not been reported. Having cloned a human galactokinase cDNA, we can determine whether patients with galactokinase deficiency have alterations in GK2. If this gene proves to be the locus for galactokinase deficiency galactosemia, it can be used to determine definitively the basis for presenile cataracts, in particular, whether this disease results from heterozygosity or other genetic alterations at this locus. The strategy used here to clone a human galactokinase gene could be used to clone various human disease genes affecting intermediary metabolism (41) for which yeast mutants are known (42) . 
